# US 2008/0286789 A1 · Genomic polymorphism for predicting therapeutic response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0286789 A1
- Document ID: US20080286789A1
- Status: Published application
- Kind: A1
- Application number: 12/110,044
- Filed: 2008-04-25
- Published: 2008-11-20
- Earliest claimed: 1999-11-15
- Assignees: University of Southern California
- Inventors: Heinz-Josef Lenz; Sheeja Thankappan Pullarkat; Yi Ping Xiong
- Web page: https://patentgrep.com/patent/US20080286789A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of genomic polymorphism to provide individualized therapeutic regimens to treat patients suffering from diseases such as cancer. The invention discloses methods for determining the efficacy or choice of chemotherapeutic drugs and regimens for use in treating a diseased patient by associating genomic polymorphism with the effectiveness of the drugs or regimens, or by associating genomic polymorphism with the intratumoral expression of a gene whereby the gene expression affects effectiveness of the drugs or regimens. In particular, the present invention provides novel methods for screening therapeutic regimens, which comprise determining a patient's genotype at a tandemly repeated 28 base pair region in the thymidilate synthase (TS) gene's 5′ untranslated region (UTR). Patients homozygous for a triple repeat will be least successfully treated with a thymidylate synthase directed drug, while those heterozygous for a triple and a double repeat will be more successfully treated, and those homozygous for a double repeat will be even more successfully treated. Those patients homozygous for the double repeat will likely suffer the least side effects from thymidylate synthase directed drugs such as 5-FU.

## Claims

### Claim 1

A method for determining the effectiveness of a therapeutic regimen for the treatment of a cancer in a subject, the method comprising:
(a) determining a genomic polymorphism in the subject with said cancer; and
(b) concluding that the therapeutic regimen will be effective if the genomic polymorphism exhibited by the subject is of a certain type.

### Claim 2 (depends on 1)

The method of claim 1 wherein the therapeutic regimen comprises administering a chemotherapeutic drug to the subject.

### Claim 3 (depends on 2)

The method of claim 2 wherein the chemotherapeutic drug is a TS directed drug.

### Claim 4 (depends on 3)

The method of claim 3 wherein the TS directed drug is a fluropyrimidine.

### Claim 5 (depends on 4)

The method of claim 4 wherein the fluoropyrimidine is 5-fluorouracil.

### Claim 6 (depends on 5)

The method of claim 5 wherein the subject is a human subject.

### Claim 7 (depends on 6)

The method of claim 6 wherein determining the genomic polymorphism of the subject comprises determining the subject's genotype at a tandemly repeated 28 base pair sequence in the thymidilate synthase gene's 5′ UTR whereby the subject will exhibit the poorest response to administration of 5-fluorouracil if the subject's genotype is homozygous for a triple repeat of the tandemly repeated sequence, a less poor response to administration of 5-fluorouracil if the subject's genotype is heterozygous for a double repeat and a triple repeat of the tandemly repeated sequence, and the best response to administration of 5-fluorouracil if the subject's genotype is homozygous for a double repeat of the tandemly repeated sequence.

### Claim 8 (depends on 6)

The method of claim 6 wherein determining the subject's genotype further comprises:
extracting genomic DNA from a biological sample of the subject;
amplifying the 5′ UTR of the thymidilate synthase gene of said genomic DNA using polymerase chain reaction; and
analyzing the polymerase chain reaction product to determine the subject's genotype.

### Claim 9 (depends on 8)

The method of claim 8 wherein analysis of the polymerase chain reaction product is performed using electrophoresis.

### Claim 10 (depends on 1)

The method of claim 1 wherein the cancer is breast cancer.

### Claim 11 (depends on 1)

The method of claim 1 wherein the cancer is colorectal cancer.

### Claim 12 (depends on 1)

The method of claim 1 wherein the cancer is gastric cancer.

### Claim 13 (depends on 1)

The method of claim 1 wherein the cancer is esophageal cancer

### Claim 14 (depends on 1)

The method of claim 1 wherein the cancer is Burkitt's lymphoma.

### Claim 15 (depends on 1)

The method of claim 1 wherein the cancer is B follicular cell lymphoma.

### Claim 16 (depends on 1)

The method of claim 1 wherein the cancer is small cell lung carcinoma.

### Claim 17

A method for predicting the effect of a therapeutic regimen for treating a cancer in a human subject wherein a chemotherapeutic drug is administered to the human, the method comprising:
associating a genomic polymorphism of the human subject with intratumoral expression of a gene wherein said gene expression influences the efficacy of said therapeutic regimen.

### Claim 18 (depends on 17)

The method of claim 17 wherein the chemotherapeutic drug is a TS directed drug.

### Claim 19 (depends on 18)

The method of claim 18 wherein the gene is thymidilate synthase gene.

### Claim 20 (depends on 19)

The method of claim 19 wherein the genomic polymorphism of the human subject is the subject's genotype at a tandemly repeated 28 base pair sequence in the thymidilate synthase gene 5′ UTR.

### Claim 21 (depends on 20)

The method of claim 20 wherein the therapeutic regimen is most effective if the subject's genotype is homozygous for a double repeat of the tandemly repeated sequence, is less effective if the subject's genotype is heterozygous for a double and a triple repeat of the tandemly repeated sequence and is least effective if the subject's genotype is homozygous for a triple repeat of the tandemly repeated sequence.

### Claim 22

A method for determining the expression level of a gene in cells of a subject, the method comprising:
determining a genomic polymorphism of the subject; and
associating the expression level of said gene with said genomic polymorphism.

### Claim 23 (depends on 22)

The method of claim 22 wherein the gene is thymidilate synthase gene.

### Claim 24 (depends on 23)

The method of claim 23 wherein the genomic polymorphism of the subject is the subject's genotype at a tandemly repeated 28 base pair sequence in the thymidilate synthase gene's 5′ UTR.

### Claim 25 (depends on 24)

The method of claim 24 wherein the expression level of said gene is highest if the subject's genotype is homozygous for a triple repeat of the tandemly repeated sequence, is less if the subject's genotype is heterozygous for a double and a triple repeat of the tandemly repeated sequence and is least if the subject's genotype is homozygous for a double repeat of the tandemly repeated sequence.

### Claim 26

A method for determining the effectiveness of a chemotherapeutic regimen wherein a TS directed drug is administered to a human subject, the method comprising:
determining the subject's genotype at a tandemly repeated 28 base pair sequence in the thymidilate synthase gene's 5′ UTR whereby the subject will exhibit the poorest response to administration of the TS directed drug if the subject's genotype is homozygous for a triple repeat of the tandemly repeated sequence, a less poor response to administration of the TS directed drug if the subject's genotype is heterozygous for a double repeat and a triple repeat of the tandemly repeated sequence, and the best response to administration of the TS directed drug if the subject's genotype is homozygous for a double repeat of the tandemly repeated sequence.

### Claim 27 (depends on 26)

The method of claim 26 wherein the TS directed drug is a fluoropyrimidine.

### Claim 28 (depends on 27)

The method of claim 27 wherein the fluoropyrimidine is 5-fluorouracil.

### Claim 29

A method for determining an appropriate chemotherapeutic regimen to treat a cancer in a subject, the method comprising:
associating a genomic polymorphism of the subject with the effectiveness of a chemotherapeutic regimen.

### Claim 30 (depends on 29)

The method of claim 29 wherein the method is used to select or reject a chemotherapeutic drug to treat the cancer.

### Claim 31

A kit for use in screening for the effectiveness of TS directed drug therapy in human subjects.

### Claim 32 (depends on 31)

The kit of claim 31 comprising:
all or some of the positive controls, negative controls, reagents, primers, sequencing markers, probes and antibodies for determining the presence or absence of the tandemly repeated 28 base-pair nucleic acid sequence that defines the genomic polymorphism in the 5′ UTR of the TS gene.

### Claim 33 (depends on 31)

The kit of claim 31 wherein the kit components may be provided in solution or as a liquid dispersion or the like.

### Claim 34 (depends on 31)

The kit of claim 31 comprising DNA tandemly repeated sequences that determine the type of genomic polymorphism of the TS gene in Tris-EDTA buffer solution preferably kept at 4° C.
